Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Kiran Madwani"'
Autor:
Michelle A. Fanale, Razelle Kurzrock, Funda Meric-Bernstam, Sattva S. Neelapu, Luis E. Fayad, Elizabeth J. Shpall, Ignacio Garrido-Laguna, Sarina A. Piha-Paul, Jennifer J. Wheler, Daniel D. Karp, Gerald S. Falchook, Fredrick B. Hagemeister, Tamara G. Barnes, Vivianne M. Velez-Bravo, Aung Naing, David S. Hong, Vivek Subbiah, Yasuhiro Oki, Kiran Madwani, S. Greg Call, Haeseong Park, Filip Janku
Clinical Study Protocol: A Phase I Trial of Sirolimus or Everolimus or Temsirolimus (mTOR inhibitor) and Vorinostat (Histone Deacetylase Inhibitor) in Patients with Advanced Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52504a9693453761dc570bbcdd6cf4a6
https://doi.org/10.1158/1078-0432.22477578.v1
https://doi.org/10.1158/1078-0432.22477578.v1
Autor:
Michelle A. Fanale, Razelle Kurzrock, Funda Meric-Bernstam, Sattva S. Neelapu, Luis E. Fayad, Elizabeth J. Shpall, Ignacio Garrido-Laguna, Sarina A. Piha-Paul, Jennifer J. Wheler, Daniel D. Karp, Gerald S. Falchook, Fredrick B. Hagemeister, Tamara G. Barnes, Vivianne M. Velez-Bravo, Aung Naing, David S. Hong, Vivek Subbiah, Yasuhiro Oki, Kiran Madwani, S. Greg Call, Haeseong Park, Filip Janku
Representative images of selected patients with therapy response.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34cf1f7c037dac86f89b6562333b4dbd
https://doi.org/10.1158/1078-0432.22477590.v1
https://doi.org/10.1158/1078-0432.22477590.v1
Autor:
Michelle A. Fanale, Razelle Kurzrock, Funda Meric-Bernstam, Sattva S. Neelapu, Luis E. Fayad, Elizabeth J. Shpall, Ignacio Garrido-Laguna, Sarina A. Piha-Paul, Jennifer J. Wheler, Daniel D. Karp, Gerald S. Falchook, Fredrick B. Hagemeister, Tamara G. Barnes, Vivianne M. Velez-Bravo, Aung Naing, David S. Hong, Vivek Subbiah, Yasuhiro Oki, Kiran Madwani, S. Greg Call, Haeseong Park, Filip Janku
In patients treated with vorinostat and sirolimus, there was a trend towards a longer median progression-free survival in patients with ECOG performance status 0 compared to ECOG 1 or 2 (not reached vs. 4.6 months, 95% CI 1.5-7.7; P = 0.06).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24604717b397ed0b8ddb6dc1ed872c70
https://doi.org/10.1158/1078-0432.22477587
https://doi.org/10.1158/1078-0432.22477587
Autor:
Michelle A. Fanale, Razelle Kurzrock, Funda Meric-Bernstam, Sattva S. Neelapu, Luis E. Fayad, Elizabeth J. Shpall, Ignacio Garrido-Laguna, Sarina A. Piha-Paul, Jennifer J. Wheler, Daniel D. Karp, Gerald S. Falchook, Fredrick B. Hagemeister, Tamara G. Barnes, Vivianne M. Velez-Bravo, Aung Naing, David S. Hong, Vivek Subbiah, Yasuhiro Oki, Kiran Madwani, S. Greg Call, Haeseong Park, Filip Janku
Dose modifications: vorinostat and sirolimus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f91712d87f833826b5c6f2ac3570779
https://doi.org/10.1158/1078-0432.22477596.v1
https://doi.org/10.1158/1078-0432.22477596.v1
Autor:
Neeraj S. Salathia, Jian-Bing Fan, Gordon B. Mills, Funda Meric-Bernstam, John V. Heymach, Richard Shen, Chen Zhao, Jonathan Toung, Kristina M. Kruglyak, Han-Yu Chuang, Ravi Vijaya Satya, Sante Gnerre, Hyunsung J. Kim, Rajyalakshmi Luthra, E. Scott Kopetz, Milind Javle, Yue Zhao, Debra L. Andrews, Goran Cabrilo, Kiran Madwani, Nishma M. Ramzanali, Xuyu Cai, Siqing Fu, Daniel D. Karp, David S. Hong, Vivek Subbiah, Helen J. Huang, Li Liu, Jill Waters, Shile Zhang, Filip Janku
Purpose: Tumor-derived cell-free DNA (cfDNA) in plasma can be used for molecular testing and provide an attractive alternative to tumor tissue. Commonly used PCR-based technologies can test for limited number of alterations at the time. Therefore, no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::411c0132f24f471ca578aa0ac2288445
https://doi.org/10.1158/1078-0432.c.6526836.v1
https://doi.org/10.1158/1078-0432.c.6526836.v1
Autor:
Neeraj S. Salathia, Jian-Bing Fan, Gordon B. Mills, Funda Meric-Bernstam, John V. Heymach, Richard Shen, Chen Zhao, Jonathan Toung, Kristina M. Kruglyak, Han-Yu Chuang, Ravi Vijaya Satya, Sante Gnerre, Hyunsung J. Kim, Rajyalakshmi Luthra, E. Scott Kopetz, Milind Javle, Yue Zhao, Debra L. Andrews, Goran Cabrilo, Kiran Madwani, Nishma M. Ramzanali, Xuyu Cai, Siqing Fu, Daniel D. Karp, David S. Hong, Vivek Subbiah, Helen J. Huang, Li Liu, Jill Waters, Shile Zhang, Filip Janku
Supplementary Tables and Figure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07ebc7d928c81a133b92df5c7f0617e8
https://doi.org/10.1158/1078-0432.22468095
https://doi.org/10.1158/1078-0432.22468095
Autor:
Michelle A. Fanale, Razelle Kurzrock, Funda Meric-Bernstam, Sattva S. Neelapu, Luis E. Fayad, Elizabeth J. Shpall, Ignacio Garrido-Laguna, Sarina A. Piha-Paul, Jennifer J. Wheler, Daniel D. Karp, Gerald S. Falchook, Fredrick B. Hagemeister, Tamara G. Barnes, Vivianne M. Velez-Bravo, Aung Naing, David S. Hong, Vivek Subbiah, Yasuhiro Oki, Kiran Madwani, S. Greg Call, Haeseong Park, Filip Janku
Protocol: Data Analysis of Patients Treated Off-protocol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a32212de11bfa2c7f9767b2a368ce45
https://doi.org/10.1158/1078-0432.22477575
https://doi.org/10.1158/1078-0432.22477575
Autor:
Neeraj S. Salathia, Jian-Bing Fan, Gordon B. Mills, Funda Meric-Bernstam, John V. Heymach, Richard Shen, Chen Zhao, Jonathan Toung, Kristina M. Kruglyak, Han-Yu Chuang, Ravi Vijaya Satya, Sante Gnerre, Hyunsung J. Kim, Rajyalakshmi Luthra, E. Scott Kopetz, Milind Javle, Yue Zhao, Debra L. Andrews, Goran Cabrilo, Kiran Madwani, Nishma M. Ramzanali, Xuyu Cai, Siqing Fu, Daniel D. Karp, David S. Hong, Vivek Subbiah, Helen J. Huang, Li Liu, Jill Waters, Shile Zhang, Filip Janku
Supplementary File 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23fc0dd087dcc288e67e7b5cb81b0e76
https://doi.org/10.1158/1078-0432.22468098
https://doi.org/10.1158/1078-0432.22468098
Autor:
Neeraj S. Salathia, Jian-Bing Fan, Gordon B. Mills, Funda Meric-Bernstam, John V. Heymach, Richard Shen, Chen Zhao, Jonathan Toung, Kristina M. Kruglyak, Han-Yu Chuang, Ravi Vijaya Satya, Sante Gnerre, Hyunsung J. Kim, Rajyalakshmi Luthra, E. Scott Kopetz, Milind Javle, Yue Zhao, Debra L. Andrews, Goran Cabrilo, Kiran Madwani, Nishma M. Ramzanali, Xuyu Cai, Siqing Fu, Daniel D. Karp, David S. Hong, Vivek Subbiah, Helen J. Huang, Li Liu, Jill Waters, Shile Zhang, Filip Janku
Supplementary File 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31488103506ac06e55d5ab69bddb811b
https://doi.org/10.1158/1078-0432.22468101
https://doi.org/10.1158/1078-0432.22468101
Autor:
Michelle A. Fanale, Razelle Kurzrock, Funda Meric-Bernstam, Sattva S. Neelapu, Luis E. Fayad, Elizabeth J. Shpall, Ignacio Garrido-Laguna, Sarina A. Piha-Paul, Jennifer J. Wheler, Daniel D. Karp, Gerald S. Falchook, Fredrick B. Hagemeister, Tamara G. Barnes, Vivianne M. Velez-Bravo, Aung Naing, David S. Hong, Vivek Subbiah, Yasuhiro Oki, Kiran Madwani, S. Greg Call, Haeseong Park, Filip Janku
Purpose:Preclinical and early clinical data suggested that combining histone deacetylase (HDAC) and mTOR inhibitors can synergistically inhibit Hodgkin lymphoma.Patients and Methods:During the dose-escalation study (ClinicalTrials.gov number: NCT0108
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f8c06129efba641b2887827aae9e91d
https://doi.org/10.1158/1078-0432.c.6529704
https://doi.org/10.1158/1078-0432.c.6529704